BioSpace News Archive

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the first quarter ended March 31, 2023.

Cue Health Inc., a healthcare technology company, reported financial results for the first quarter 2023.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced financial results for the three months ended March 31, 2023.

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the management team will participate in and attend one-on-one meetings at two upcoming in-person investor conferences.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the first quarter ended March 31, 2023.

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 105.9 million in the first quarter of 2023 and EBITDA of minus NOK 1.2 million.

UNION therapeutics A/S announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on hidradenitis suppurativa at the 4th Annual Dermatology Drug Development Summit Europe on May 22-24, 2023, in Berlin, Germany.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced it will provide its inactivated COVID-19 vaccine, CoronaVac®, to self-paying groups in Hong Kong.

Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of dementia and other degenerative diseases

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Susan Altschuller, Ph.D. as chief financial officer, effective May 15, 2023.